 | Up a level |
Honecker, F; Aparicio, J; Berney, D; Beyer, Jörg; Bokemeyer, C; Cathomas, R; Clarke, N; Cohn-Cedermark, G; Daugaard, G; Dieckmann, K-P; Fizazi, K; Fosså, S; Germa-Lluch, J R; Giannatempo, P; Gietema, J A; Gillessen, Silke; Haugnes, H S; Heidenreich, A; Hemminki, K; Huddart, R; ... (2018). ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of oncology, 29(8), pp. 1658-1686. Oxford University Press 10.1093/annonc/mdy217
von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mjhic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R; Swiss Group for Clinical Cancer Research, (SAKK) (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of oncology, 23(2), pp. 531-6. Oxford: Oxford University Press 10.1093/annonc/mdr126
Rothschild, S; Amrein, Michael; Riether, Carsten; Gautschi, O; Schuster, N; Li, Q; Savic, S; Schneider, M; Biaggi, C; Bubendorf, L; Brutsche, M; Zippelius, A; Zander, T; Betticher, D; Früh, M; Stahel, R; Cathomas, R; Rauch, Daniel; Pless, M; Ochsenbein, Adrian; ... (October 2017). CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). Journal of thoracic oncology, 12(11S2), S1864-S1865. Elsevier
